Page 2 - Moral Small News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Moral small. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Moral Small Today - Breaking & Trending Today

A new administration is taking the White House—will the 'onshore' drug manufacturing movement keep building?

Dec 22, 2020 3:00am
Drug manufacturers are looking for a more local future for production post-COVID-19. (Pixabay)(Monica Alleven/Fierce Wireless)
With the COVID-19 pandemic perhaps entering its final phase as the first wave of vaccines approaches the market, one question left unanswered is the future of onshoring drug manufacturing an initiative that reached fever pitch in 2019 as nationwide lockdowns and geopolitical tension cast a spotlight on the global supply chain.
In 2019, congressional leaders across the aisle picked up steam on a suite of bills aimed at incentivizing and driving manufacturing redundancy in the U.S. to combat China and India s dominance in generic medicines and active pharmaceutical ingredients (APIs). ....

United States , South Carolina , Grand Rapids , Industrial Park , South Korea , South Korean , Joe Biden White , Martin Meeson , Baltimore Camden , Baltimore Bayview , Phlow Corporation , Development Authority , Oval Office , Exchange Commission , Us International Development Finance Corporation , Human Service Biomedical Advanced Research , Department Of Health , Strategic National , Warp Speed , Optimal Scale Up , Tech Transfer , Moral Small , Joe Biden White House , Fujifilm Diosynth Biotechnologies , Development Finance Corporation , House Democrats ,

Young but ambitious Taysha lays out $76M for commercial gene therapy plant

RA Session II, founder, president and CEO of Taysha (Taysha Gene Therapies)
Taysha Gene Therapies hit the ground running when it launched this spring, cruising through a $95 million series B straight to a $100 million IPO in September. With its lead program now approved for human trials in Canada, the company is sketching out plans for what it hopes will become its prime commercial manufacturing site.
Taysha leased a 187,000-square-foot commercial-scale manufacturing facility in Durham, North Carolina, planning to invest $75 million to kit out the facility for preclinical, clinical and commercial gene therapy production. It’s also due to receive up to $9.4 million in state and local incentives for the project, Taysha said in a release. ....

North Carolina , United States , Suyash Prasad , Fred Porter , Queen University , University Of Texas Ut Southwestern Medical Center , Health Canada , Taysha Gene Therapies , Optimal Scale Up , Tech Transfer , Moral Small , Southwestern Medical Center , வடக்கு கரோலினா , ஒன்றுபட்டது மாநிலங்களில் , சுயஷ் பிரசாத் , ஃப்ரெட் போர்டர் , ராணி பல்கலைக்கழகம் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் உட் தென்மேற்கு மருத்துவ மையம் , ஆரோக்கியம் கனடா , தாய்ஷ்ா கீந் சிகிச்சைகள் , உகந்த அளவு மேலே , தொழில்நுட்பம் பரிமாற்றம் , வாய்வழி சிறிய , தென்மேற்கு மருத்துவ மையம் ,

Targeted delivery, oral vaccines and mRNA 2.0: The next generation of drugs and prophylactics in the fight against COVID-19

Dec 22, 2020 9:15am
Big name pharmas, budding biopharmas and research institutions the world over are plugging away on the next generation of drugs and vaccines against the COVID-19 pandemic. (Bill Oxford/Getty Images)
As the chapter closes on the first year of the COVID-19 pandemic, drugmakers are hard at work bolstering the defenses mounted in 2020 and they re looking at new formulations and delivery methods to bring vaccines and therapies to more people around the world.
Can follow-up shots ease the harsh cold chain requirements for mRNA vaccines? Could supplies be extended with a vaccine that works at one dose rather than two? And could COVID-19 meds be improved by targeting the site where the disease hits hardest? ....

Mikael Dolsten , Jim Wilson , Kernal Biologics , University Of Texas , University Of Pennsylvania , Merck Co , University Of Hong Kong , Optimal Scale Up , Tech Transfer , Moral Small , Business Insider , Hong Kong , Eureka Therapeutics , ஜிம் வில்சன் , கர்னல் உயிரியல் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் , பல்கலைக்கழகம் ஆஃப் பென்சில்வேனியா , மெர்க் இணை , பல்கலைக்கழகம் ஆஃப் ஹாங் காங் , உகந்த அளவு மேலே , தொழில்நுட்பம் பரிமாற்றம் , வாய்வழி சிறிய , வணிக உள் , ஹாங் காங் , யுரேகா சிகிச்சை ,

'We will not return to the old ways of working': Drugmakers weigh in on returning to work, post-COVID-19 life

Dec 22, 2020 9:00am
Drugmakers believe COVID-19 may change the ways of working for good, even after the pandemic eases. (Getty Images)
As COVID-19 vaccines are rolling out in different parts of the world, perhaps it’s finally time to talk about life after the pandemic. But biopharma companies believe it’s too early to put a specific timeline on turning that page now.
Despite all the unknowns, though, one thing seems certain: How drugmakers conduct their business will change.
After navigating the past few months, “one thing is clear to us: We will not return to the old ways of working after the corona pandemic,” Bayer spokesman Markus Siebenmorgen said. ....

New Jersey , United States , Markus Siebenmorgen , Broad Institute , Bristol Myers Squibb , Eli Lilly , Optimal Scale Up , Tech Transfer , Moral Small , Boston Marriott Long Wharf , Big Biotech , Project Explore , புதியது ஜெர்சி , ஒன்றுபட்டது மாநிலங்களில் , மிச Ou ரி , மார்கஸ் சிஎபேன்மோர்கேன் , பரந்த நிறுவனம் , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் , எலி லில்லி , உகந்த அளவு மேலே , தொழில்நுட்பம் பரிமாற்றம் , வாய்வழி சிறிய , போஸ்டன் மேரியட் நீண்டது வார்ஃப் , பெரியது பயோடெக் , ப்ராஜெக்ட் ஆராயுங்கள் ,

WuXi lays out €150 million to take over Bayer plant in Germany, boosting pandemic supply network

Dec 21, 2020 11:00am
WuXi Biologics will pay Bayer €150 million to take charge at the company s drug product manufacturing plant in Wuppertal, Germany one of two German plants WuXi picked up from the drugmaker this year. (Bayer)
Shanghai s WuXi Biologics is ending the year how it started: with plans to take charge at a Bayer facility in Germany. The company s latest site acquisition follows deals for three U.S. facilities this year, part of WuXi Bio s gung-ho expansion efforts outside of China.
WuXi Bio is stumping up €150 million ($183.3 million) to take over Bayer s drug substance manufacturing facility in Wuppertal, Germany. The companies further plan to strike up a long-term sublease agreement and a transition service contract, Bayer and WuXi Bio said in a release. ....

United States , Nordrhein Westfalen , Wuxi Biologics , Optimal Scale Up , Tech Transfer , Moral Small , ஒன்றுபட்டது மாநிலங்களில் , னோற்ர்ேன் வெஸ்ட்ஃபாலன் , உகந்த அளவு மேலே , தொழில்நுட்பம் பரிமாற்றம் , வாய்வழி சிறிய ,